Skip to content
Screener
electroCore, Inc. logo

electroCore, Inc.

ECOR

electroCore is a bioelectronic technology company focused on developing and commercializing non-invasive vagus nerve stimulation (nVNS) and neuromodulation therapies.

Market cap
$96.02M+158%
Revenue$37.0M+33.5%
Net income-$14.8M-11.5%
Free cash flow-$9.7M+8.5%
EPS (diluted)-$1.66-2.5%
Trailing twelve months · change vs. prior year

Earnings

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$10.9M
EPS estimate-$0.26

Financials

Q2 2026

Income statement

See full
Revenue$9.5M+28.0%
Gross profit$8.2M+26.9%
Operating income-$2.8M+20.9%
Net income-$3.1M+16.7%
EPS (diluted)-$0.33+25.0%

Balance sheet

See full
Cash & equivalents$8.5M+135%
Total debt$9.6M+126%
Total equity-$2.8M-351%
Total assets$17.1M+17.2%

Cash flow

See full
Operating cash flow-$3.5M-465%
CapEx$4.0K-84.0%
Free cash flow-$3.5M-444%

Valuation & ratios

Valuation

See full
Market cap$90.61M+158%
Enterprise value$91.67M+156%
P/S2.5×+1.2×

Profitability

See full
Gross margin87.1%+1.5pp
Operating margin-37.6%-6.3pp
Net margin-40%-5.7pp
FCF margin-26.4%

Returns & leverage

See full
Current ratio1.2×+0.1×

Segments

By segment

See full
Bioelectronic Innovations$9.5M+28.0%

Competitors

Profile

electroCore is a bioelectronic technology company focused on developing and commercializing non-invasive vagus nerve stimulation (nVNS) and neuromodulation therapies. The company provides proprietary handheld and wearable devices designed to treat primary headache conditions, chronic pain, and fibromyalgia, while also offering consumer products for general wellness and human performance. Its core value proposition lies in providing non-invasive, drug-free alternatives to traditional pharmaceutical treatments for neurological and chronic pain disorders.

Competitive position

The company is a pioneer in non-invasive vagus nerve stimulation with a significant patent portfolio and established government contracts, though it faces competition from large pharmaceutical firms and emerging neuromodulation device makers.

GeographiesUnited States, United Kingdom, European Economic Area
Customer segmentsGovernment healthcare agencies, Chronic pain patients, Military and defense, Wellness-conscious consumers
Business modelDirect-to-consumer, B2B2C, Government contracting, Razor-and-blade (device and refills)
SuppliersThird-party contract manufacturers, Electronic component suppliers, Software developers, Specialty pharmacies
CustomersU.S. Department of Veterans Affairs, U.S. Department of Defense, UK National Health Service, Retailers like Best Buy, Direct-to-consumer patients
Listed2018
Employees62.0
CEOThomas J. Errico
FilingsSEC EDGAR

FAQ

What is electroCore, Inc.'s market cap?
electroCore, Inc. (ECOR) has a market capitalization of $96.0M and trades on NASDAQ.
What is electroCore, Inc.'s revenue and profitability?
electroCore, Inc. generated $37.0M in trailing twelve-month revenue with a net loss of $14.8M, representing a net margin of -40.0%. Gross margin stands at 87.1%, with free cash flow of -$9.7M. The latest reported period is Q2 2026.
Who are electroCore, Inc.'s competitors?
electroCore, Inc.'s key competitors include Eli Lilly and Company, AbbVie, Alphabet Inc., and others. These companies compete in similar markets and product categories.
Who does electroCore, Inc. partner with?
electroCore, Inc.'s notable partners include Lovell Government Services, Best Buy, Rehabmart, and others.
What subsidiaries does electroCore, Inc. have?
electroCore, Inc.'s subsidiaries include NeuroMetrix, electroCore U.K. Ltd., electroCore Germany GmbH.
Where is electroCore, Inc. headquartered?
electroCore, Inc. is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 2018.